First-in-man mesenchymal stem cells for radiation-induced xerostomia (MESRIX):study protocol for a randomized controlled trial. by Grønhøj, Christian et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
First-in-man mesenchymal stem cells for radiation-induced xerostomia (MESRIX)
Grønhøj, Christian; Jensen, David Hebbelstrup; Glovinski, Peter Viktor; mpw981, mpw981;
Jensen, Allan Bardow; Oliveri, Roberto Stefan; Specht, Lena; Thomsen, Carsten; Darkner,
Sune; Kiss, Katalin; Fischer-Nielsen, Anne; von Buchwald, Christian
Published in:
Trials
DOI:
10.1186/s13063-017-1856-0
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Grønhøj, C., Jensen, D. H., Glovinski, P. V., mpw981, M., Jensen, A. B., Oliveri, R. S., ... von Buchwald, C.
(2017). First-in-man mesenchymal stem cells for radiation-induced xerostomia (MESRIX): study protocol for a
randomized controlled trial. Trials, 18(1), [108]. https://doi.org/10.1186/s13063-017-1856-0
Download date: 03. Feb. 2020
STUDY PROTOCOL Open Access
First-in-man mesenchymal stem cells for
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Abstract
Background: Salivary gland hypofunction and xerostomia are major complications following radiotherapy for
head and neck cancer and may lead to debilitating oral disorders and impaired quality of life. Currently, only
symptomatic treatment is available. However, mesenchymal stem cell (MSC) therapy has shown promising results
in preclinical studies. Objectives are to assess safety and efficacy in a first-in-man trial on adipose-derived MSC
therapy (ASC) for radiation-induced xerostomia.
Methods: This is a single-center, phase I/II, randomized, placebo-controlled, double-blinded clinical trial. A total
of 30 patients are randomized in a 1:1 ratio to receive ultrasound-guided, administered ASC or placebo to the
submandibular glands. The primary outcome is change in unstimulated whole salivary flow rate. The secondary
outcomes are safety, efficacy, change in quality of life, qualitative and quantitative measurements of saliva, as well
as submandibular gland size, vascularization, fibrosis, and secretory tissue evaluation based on contrast-induced
magnetic resonance imaging (MRI) and core-needle samples. The assessments are performed at baseline (1 month
prior to treatment) and 1 and 4 months following investigational intervention.
Discussion: The trial is the first attempt to evaluate the safety and efficacy of adipose-derived MSCs (ASCs) in
patients with radiation-induced xerostomia. The results may provide evidence for the effectiveness of ASC in
patients with salivary gland hypofunction and xerostomia and deliver valuable information for the design of
subsequent trials.
Trial registration: EudraCT, Identifier: 2014-004349-29. Registered on 1 April 2015.
ClinicalTrials.gov, Identifier: NCT02513238. First received on 2 July 2015.
The trial is prospectively registered.
Keywords: Mesenchymal stem cells, Xerostomia
* Correspondence: c.gronhoj@gmail.com
1Department of Otorhinolaryngology, Head and Neck Surgery and
Audiology, Rigshospitalet, University of Copenhagen, Section 2071,
Blegdamsvej 9, 2100 Copenhagen, Denmark
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Grønhøj et al. Trials  (2017) 18:108 
DOI 10.1186/s13063-017-1856-0
Background
Xerostomia is the term used for a subjective feeling of
dry mouth. Xerostomia can be coexisting with or with-
out a reduced secretion of saliva, although xerostomia is
generally perceived only when unstimulated whole saliva
flow rate is reduced by more than 40–50% [1]. Thus, a
decreased (salivary gland hypofunction) or pathologically
reduced saliva secretion (hyposalivation) will severely im-
pact quality of life and may lead to dental decay. The three
main causes of severe xerostomia and hyposalivation are
adverse effects of medication intake (polypharmacy and/
or xerogenic medications), Sjögren’s syndrome, and radi-
ation therapy for head and neck cancer. With regards to
cancer chemotherapy, studies suggest that in some pa-
tients it may induce temporary salivary gland hypofunc-
tion and xerostomia during and following treatment,
while other patients are not affected to a noticeable extent;
however, no firm conclusions can be drawn from the med-
ical literature [2]. Radiation therapy plays a major role in
the curative treatment of most head and neck cancers, ei-
ther as a single modality, or in combination with chemo-
therapy, surgery, or both. Radiation therapy significantly
increases local tumor control and chance of survival, but
despite more advanced methods (intensity-modulated ra-
diation therapy, IMRT), a significant proportion of the ra-
diation is deposited in the normal tissue surrounding the
tumor. The long-term effect of radiation on salivary gland
tissue is deterioration of gland function. [3, 4]. Salivary
gland dysfunction after radiation therapy predisposes to a
variety of undesirable conditions directly or indirectly as a
result of decreased salivary flow rate as well as changed
composition and increased viscosity of saliva and include
xerostomia, impairment of oral functions due to insuffi-
cient wetting (i.e., speech, chewing, and swallowing) and
reduced lubrication of mucosal surfaces and of the
ingested food. Furthermore, the oral mucosa is prone to
frictional trauma and ulceration. In addition, a reduced
salivary flow rate results in a reduced clearance of the oral
cavity, thus leading to microbial overgrowth which, in
addition to other factors, may result in rampant dental
caries, dental erosion, and oral candidiasis [2, 5].
The average total dose range which represents the
threshold for a significant reduction in salivary flow rate is
26–39 Gray (Gy) [6–10]. The dose causing toxicity in 50%
of individuals (TD 50) is likely to be approximately 40 Gy
[11], which is similar to the TD 50 [12] estimated for sub-
mandibular hypofunction [13]. The methods used to re-
duce the incidence of xerostomia after radiation is
prevention (including more advanced radiation techniques
(IMRT or proton therapy), radio-protective agents (ami-
fostine and Tempol [14]), and the more recently proposed
stem cell-sparing radiation therapy [15]).
A number of strategies to improve salivary gland func-
tion after radiation therapy have been developed, but all
are symptomatic treatments only able to stimulate the
function of the residual salivary gland tissue or provide
short-term lubrication. These strategies include pharma-
cological agents; for example, sialogogues (pilocarpine,
cevimeline, etc.), saliva stimulants (sugar-free, nonerosive
lozenges, chewing gum, and custom-made, nonerosive
weak-acidic candy) [16], and the use of oral lubricants and
saliva substitutes [17].
Stem cells have been identified as a potential treatment
modality for a wide variety of cell degenerative disorders
by virtue of their ability to differentiate into different spe-
cialized cell types. Most of the early work on stem cells
has been performed in embryonic stem (ES) cells which
are derived from the inner cell mass of a blastocyst em-
bryo. The clinical use of these cells as therapeutic agents
is currently very limited, both due to histocompatibility
problems and to their potential ability to form malignant
teratomas. Problems with histocompatibility have been
improved with the development of induced pluripotent
stem cells (iPS cells). In contrast to ES and iPS, which are
both pluripotent stem cells, i.e., the ability to differentiate
into cells deriving from all three primary germ layers,
ectoderm, mesoderm, and endoderm; adult stem cells are
defined as multipotent, i.e., with a narrower differential
ability. In this respect, mesenchymal stem cells (MSCs)
have gained considerable attention, since they are readily
available from, e.g., bone marrow and adipose tissue, and
have been characterized and investigated in a wide variety
of preclinical studies and clinical trials.
Originally described more than 40 years ago, MSCs
reside in almost all connective tissues [18]. More
recently, there has been an increasing awareness that MSCs
have a number of interesting secretory paracrine bystander
characteristics including anti-inflammatory, antiapoptotic,
immunomodulatory, angiogenic, and trophic (tissue-regen-
erating) properties. Notably, MSCs have shown promising
results in preclinical studies for the treatment of xerostomia
including radiation-induced xerostomia [19].
The objectives of the current trial are to assess the safety
and feasibility of autologous adipose tissue-derived MSCs
administered for radiation-induced salivary gland hypo-
function and xerostomia in head and neck cancer patients.
Head and neck cancer is the sixth most common malig-
nancy worldwide, and the majority of these patients are at
an advanced disease stage at presentation and are treated
with chemotherapy, radiotherapy, or both [20, 21]. The
project can potentially help to develop a clinically relevant
treatment option for the growing number of patients suf-
fering from xerostomia after radiotherapy.
Methods
Primary outcome
Primary outcome is change in unstimulated whole saliv-
ary flow rate.
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Secondary outcomes
Secondary outcomes are:
 Safety, including adverse events (AEs) and severe
adverse events (SAEs). All measures of AEs will be
graded according to Common Terminology Criteria
for Adverse Events (CTCAE) [22]. Since this is a
local treatment with adipose-derived MSCs (ASCs)
the primary safety measures are:
Pain at injection site (grade 1: mild pain, grade
2: moderate pain; limiting instrumental activities
of daily living (ADL), grade 3: severe pain; limiting
self-care ADL)
Oral discomfort (grade 1: mild discomfort; not
interfering with oral intake, grade 2: moderate
pain; interfering with oral intake, 3: disabling pain;
tube feeding or total parental nutrition indicated)
Infection (grade 1: localized; local intervention
indicated, grade 2: oral intervention indicated
(antibiotic, antifungal, antiviral), grade 3:
intravenously administered (IV) antibiotic,
antifungal, or antiviral agent indicated; or
radiological, endoscopic, or operative intervention
indicated, grade 4: life-threatening consequences;
urgent intervention needed)
 Unstimulated and stimulated whole saliva and
selective submandibular saliva flow rate and
composition of saliva
 Complaints of xerostomia as evaluated by a
physician and patient questionnaire
 Measurement of volume, fibrosis, and
vascularization change of submandibular glands
based on magnetic resonance imaging (MRI)
 Morphological changes of the gland tissue, e.g.,
degree of atrophy, fibrosis, inflammation, and
amount of specialized acinic cells, including the
duct/acinic/myoepithelial cell ratio, in histological
sections from core-needle biopsies taken pre
(baseline) and post intervention (4 months).
An expert head and neck pathologist blinded to
treatment of participants will evaluate the two sets
of biopsies for changes
Late complications – safety
To detect late complications or late AEs all study
participants who received ASC are invited for a
check-up 1 year and 3 years after treatment. Whether
or not participants consent to a late check-up, the
principal investigator (CG) will contact participants by
telephone to ensure that no subjective complaints
have befallen. In case of subjective complaints, partic-
ipants will be encouraged to meet for a physical
examination.
Trial design
This is a randomized, placebo-controlled, phase I/II trial
with double blinding (see Figs. 1 and 2, and for the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) Checklist, see Additional file
1). All participants will undergo a mini liposuction from
which ASCs will be ex vivo expanded in a Good Manu-
facturing Practice (GMP)-approved clean room facility.
The Good Clinical Practice Committee performs data
monitoring, and is independent from the sponsor and
has no competing interests.
One month prior to the liposuction, participants will
undergo a MRI scan of the submandibular glands, fill
out questionnaires on quality of life, and undergo saliva
measurements. Also, all patients will have blood samples
analyzed for anti-HIV I/II, HBsAg, anti-HBc, anti-HCV,
and syphilis to fulfill the requirements in the Danish Tis-
sue Act, as well as relevant kidney parameters to secure
adequate renal function when using MRI contrast (see
below). A core-needle sample of one of the submandibu-
lar glands and abdominal liposuction (approximately 60
ml of adipose tissue) are performed for all participants.
Approximately 14 days following liposuction, partici-
pants will have ASCs or placebo injected in the subman-
dibular glands on an outpatient basis. Subjects will
subsequently undergo a saliva measurement, contrast-
induced MRI and fill out questionnaires at baseline, 4
weeks post intervention and 4 months post intervention.
Finally, at the 4-month visit, a small biopsy is taken from
one of the two submandibular glands. The procedure
takes place under local anesthesia. Histology is deter-
mined (samples are blinded to the pathologist) (Fig. 1).
Randomization
At inclusion to the study protocol, each participant will
be given consecutive numbers starting with number 1.
To randomize participants to either placebo or MSCs we
will use a table of random numbers, generated by a com-
puter program (http://www.randomization.com). This table
with randomization numbers will only be available to speci-
fied personnel at the Tissue Center, Department of Clinical
Immunology (Rigshospitalet).
Amount of ASCs required for injection
Based on published animal studies the amount of cells
given to mice for xerostomia varies from 2 × 105 to 2 ×
106 [23]. To convert these murine data to a realistic dose
in humans we have extrapolated numbers based on the
following data: the volume density of submandibular
glands very closely approximates 1 mg/mm3 (1.06–1.07
mg/mm3) [24]. In the murine studies on radiotherapy,
the mean gland weight was approximately 350 mg,
which corresponds to an approximate volume of 350
mm3. Accordingly, the murine dose per gland volume is
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approximately 2.86 × 105 to 2.86 × 106 ASC/cm3 gland
(when calculated from either 1 × 105 to 1 × 106). The vol-
ume of the submandibular gland in human subjects after
radiotherapy is 6.6–7.9 cm3 [25]. This corresponds to an
approximate dose per patient of between 1.9 × 106 to
2.3 × 106, or 1.9 × 107 to 2.3 × 107 cells per submandibu-
lar gland. From the above assumptions, and in order not
to administer an inadequate number of cells, we have
chosen to proceed with the maximum dose correspond-
ing to 2.8 × 106 ASC/cm3 gland, i.e., a maximum total
dose per patient of approximately 4.48 × 107 ASCs (see
below). However, to standardize the dose administered
to patients, the amount administered will be standard-
ized to the size of their submandibular glands, as de-
scribed below.
Injection of the ASCs or placebo suspensions into
the submandibular glands will be performed by the
principal investigator (CGL) under local anesthesia
using ultrasonic guidance and sterile technique. The
ASCs will be suspended in isotonic NaCl (0.9 mg/ml)
and human albumin (HA) 1% to a final volume of 2
ml. Placebo will be 2 ml of isotonic NaCl (0.9 mg/ml)
and HA 1%. After receiving the ASC suspension or
the placebo suspension, the surgeon (the principal in-
vestigator) will identify the submandibular glands and
inject the ASC suspension. Calculation of injected
number of ASCs per participant rests on the follow-
ing calculation:
Suspensionml ¼ 2:8  106 ASCcm3  Volumecm3 ;
where volume is the volume of the submandibular
gland, and a gland volume of approximately 7–8 cm3 is
the norm. Therefore, the amount of ASCs given to each
participant will be approximately: 2:8  106 ASCcm3  8c
m3  2 ¼ 4:48 106 ASCs in total.
Fig. 1 Overview of the study process
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If the expanded number of ASCs does not fulfill the
above criteria, it is accepted to diminish the number to a
minimum of 50% of the calculated dose.
Justification for patient population
In order to standardize the participant population, we
choose to only include participants treated for a human
papilloma virus (HPV)-positive oropharyngeal squamous
cell carcinoma, and to exclude patients with severe
salivary gland hypofunction (hyposalivation, e.g., whole
saliva flow rate <0.05 ml/min), as this population most
likely will not benefit from this treatment. This will be
assessed by a preliminary questionnaire and a subse-
quent saliva flow rate measurement before inclusion.
Eligibility criteria
Evaluation of eligibility criteria and Consent Forms are
collected by the primary investigator.
Inclusion criteria:
 Previous radiotherapy for a T1–T2 and N0, N1, or
N2a, HPV-positive oropharyngeal squamous cell
carcinoma with bilateral irradiation of the neck
 2 years’ follow-up without recurrence
 Clinically reduced salivation and hyposalivation,
evaluated by a screening
◦ Unstimulated whole saliva flow rate in the range
of 0.05–0.20 ml/min
 Informed consent
 Grades 1–3 xerostomia as evaluated by the “Udvalg
for Kliniske Undersøgelser” (UKU) Side-effect Rating
Scale [26]
Exclusion criteria:
 Any cancer in the previous 2 years
 Ongoing xerogenic medications
 Any other diseases of the salivary glands, e.g.,
Sjögren’s syndrome, sialolithiasis, etc.
 Pregnancy or planned pregnancy within the
next 2 years
 Breastfeeding
 Any other disease/condition judged by the
investigator to be grounds for exclusion
 Treatment with an anticoagulant that cannot be
stopped during the intervention period
 Failure of expanding up to 50% of the calculated
dose of ASC
 Withdrawal of informed consent
Fig. 2 Schedule of enrollment, interventions, and assessments
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Criteria for withdrawal of subjects under study
 Pregnancy
 Infection of the transplanted site
 Allergy to local anesthetic
 Withdrawal of consent from participants
 In case of withdrawal or dropout before assessment
of efficacy patients will be replaced to ensure that a
total of 30 patients complete the study
Surgical method for mini liposuction
The procedure is done in an outpatient setting, and
performed under sterile conditions according to local
guidelines. Six milliliters of local anesthesia (lidocaine
1%) is injected subcutaneously at two injection sites of
the lateral abdomen. Two 5-mm incisions are then made
and Klein’s solution is injected with a blunt infiltrator
through the incisions. The fatty tissue is harvested from
the abdomen with a 3-mm blunt cannula 23 cm in
length, coupled to the MonoJect 60-ml syringe with a
blunt and Toomey tip (Teico Healthcare). The harvested
lipoaspirate is sedimented in the syringe. Any oil layer at
the top or aqueous layer at the bottom is removed. By
this procedure the middle layer of fat tissue is obtained
and will be transported in a sterile plastic bag for the
isolation of ASCs.
Surgical method for submandibular gland biopsy
This procedure takes place in an outpatient settings. A
biopsy will be taken 14 days before injecting the ASCs
and 4 months after injection. The biopsy procedure is
carried out under sterile conditions; in local anesthesia
with lidocaine with epinephrine 0.5% an ultrasound-
guided, core biopsy of one of the glands is taken. Partici-
pants are randomized for biopsy of either the right or
left gland. Each biopsy will be fixed in 4% formalin and
sent for histology.
Surgical method for injection of ASCs or placebo in the
submandibular gland
The procedure will be performed without local anesthesia
in an outpatient setting. The surgeon will receive two
syringes of the sterile ASC suspension or placebo, each of
1 ml (total of 2 ml). The suspensions are injected into each
submandibular gland guided by ultrasound. The ASC sus-
pension will be deposited in two areas (superficial and
deep lobe) with equal volume per site (0.5 ml) to ensure
equal distribution of the suspension. The subject will
afterwards receive a small bandaid, which can be removed
the same day. The participant will be administered over-
the-counter pain relief.
Assessment of xerostomia and subjective treatment
outcome
The subjective effect of the treatment is assessed by a
100-mm Visual Analog Scale of xerostomia filled out by
the patient [27] and a physician-rated questionnaire [28],
both carried out at baseline as well as at 1 and 4 months
after treatment (Fig. 1).
Assessment of salivary flow rate and objective treatment
outcome
Changes in the secretion rate of the unstimulated whole
saliva in the oral cavity is probably the most important
parameter for the biological development of xerostomia
and accompanying pathological oral conditions. Whole
saliva, e.g., the secretions from the major and minor
salivary glands are mixed in the oral cavity. A precise de-
termination of this value is crucial for the assessment of
efficacy in this trial. For determination of the saliva flow
rate, whole saliva will be collected between 2 p.m. and 3
p.m. for all collections to take the salivary diurnal vari-
ation into account. Participants will refrain from eating,
drinking, smoking and administering oral hygiene for 2
h prior to collection. After being seated upright in a
chair, subjects relax for 5 min and are then instructed to
make as few movements as possible, including swallow-
ing, during the collection. At baseline, 1 and 4 months
after treatment, unstimulated whole saliva will be col-
lected using the spitting method [29] where participants
spit their saliva into a collection container over a period
of 15 min. The salivary flow rate (SFR) (ml/min) is
determined as the increase in weight of the container di-
vided by the collection time in minutes. After the collec-
tion of unstimulated saliva, the subjects are instructed to
chew on 1 g of sterile paraffin wax. Participants will
chew for 60 s, and clear the oral cavity for saliva.
Subsequently, as the glands are now in a stimulated
state, participants will continue chewing the paraffin
wax and expectorate into a saliva collector for the
duration of 5 min. Subsequently, testing of the subman-
dibular glands will be performed.
To assess ASC efficacy on the submandibular glands,
saliva is also collected directly from the floor of the
mouth in an unstimulated and stimulated state. The flow
rate of the submandibular glands will be assessed by the
swab method with cotton rolls placed buccally in each
maxillary molar region to block the orifices of the par-
otid ducts and cotton rolls under the tongue in the floor
of the mouth to collect submandibular/sublingual saliva.
Immediately prior to the start of collection participants
will be asked to swallow. Unstimulated saliva testing will
be performed with neutral cotton rolls (Salivette®,
Sarstedt, Nümbrecht, Germany) and stimulated saliva
testing with cotton rolls with 20 mg citric acid (Salivette
with citric acid®, Sarstedt, Nümbrecht, Germany). For
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both measurements, collections takes place during a
period of 3 min. Saliva flow rates are determined by
weight (1 g equals 1 ml of saliva) with cotton rolls
weighed before collection and reweighed after. The flow
rates are calculated as the increase in weight during col-
lection and expressed as milliliters per minute. Saliva
from the cotton rolls will be extracted by centrifuga-
tion (1500 g) and analyzed for its composition. From
each of these collections, saliva will be aliquoted and
stored at −80°C.
Chemical analysis of saliva
Whole saliva contains a large number of bacteria and epi-
thelial cells as well as gingival crevicular fluid. Therefore,
whole saliva is normally not suited for the analysis of sen-
sitive chemical parameters. For this purpose, noncontami-
nated, selectively collected saliva from individual glands:
i.e., parotid and submandibular/sublingual saliva is more
suitable. The following analyzes will be performed on the
collected saliva: pH and bicarbonate level by ionic balance
estimation [30], sodium, potassium, calcium, phosphate,
chloride and fluoride [16], total protein, selected proteins
[31], and amylase [32]. Chemical analysis will provide an
estimate of dental and mucosal protective capacity of the
saliva before and after treatment.
MRI analysis of the submandibular glands
A 3.0-Tesla, four-channel head coil and a dual-channel
neck coil are employed to obtain hsMRI images of sub-
jects (Siemens Magnetom Verio, Erlangen, Germany).
Volumetric and tissue-specific analysis will be per-
formed based on axial and coronal sequences with 72
slices and 4-mm slice thickness including diffusion-
weighted and dynamic contrast-induced sequences. The
contrast agent used is gadolinium (“Gadovist”).
Statistical analyses
Data will be analyzed with SPSS v. 24 (IBM) or R statis-
tics. We will use Excel or Access databases for collecting
and entering data. All data will be double entered. End
of trial is defined as: last patient’s last visit (LPLV).
The results on salivary flow rate will be calculated as a
percentage change in salivary flow rate (from baseline)
in the group of participants given ASCs compared to the
score change in the control group.
Histologically, the composition of glandular tissue in
the submandibular gland will be calculated from before
(baseline) and 4 months after the intervention (Fig. 1).
The differences between the intervention and the pla-
cebo group will be calculated by a nonpaired t test or, al-
ternatively, a nonparametric test, if the conditions for
parametric tests are not present. Differences are consid-
ered statistically significant if the two-sided p value is
less than 0.05.
Sample size calculation
The following sample size determination is based on a
nonpaired t test. The minimal change in salivary flow
rate that we want to be able to determine is 50%.
Standard deviation (SD) of a salivary flow rate meas-
urement can, using the spitting method in healthy par-
ticipants and under completely standardized conditions,
be minimized to about 20%. The SD can vary greatly
and we have, therefore, in this test used a value from the
published medical literature [33] for persons with re-
duced unstimulated whole salivary flow rate (from 0.00
to 0.20 ml/min) and/or hyposalivation (<0.10 ml/min)
indicating a relative SD of 58% of these groups. How-
ever, since we are interested in a comparison of change
scores (change from baseline to after treatment) between
the intervention and placebo groups we apply the rule of
thumb that the SD of the change score equals SD/20.5
which equals an SD of approximately 41%. The power is
set at (1 − β): 90%. Significance level (α) is set at 0.05.
This is a trial with a continuous response variable from
independent control and experimental research unit
with one control per experimental research unit. If the
true difference in the change score between experimen-
tal and control means is 50%, we will need to study 15
participants for the experimental intervention and 15 pa-
tients as a control population in order to reject the null
hypothesis that the population means of the experimen-
tal and control groups are equal with a study power of
90%. The Type I error probability associated with this
test of this null hypothesis is 0.05.
All investigators will have access to the final trial
dataset.
Discussion
This first-in-man trial aims to establish the safety, effi-
cacy, and feasibility of autologous, adipose-derived stem
cell therapy for patients with radiation-induced xerosto-
mia. In addition, it provides an opportunity to advance
trial methodology for the assessment of the putative role
of stem cell therapy and provide suggestions for the de-
sign of subsequent trials to verify potential efficacy. To
establish the safety profile of the intervention, selection
and timing of appropriate outcomes have been guided
by similar intervention studies [34], and our trial design
facilitates conditions for assessment of short- and long-
term changes and complications.
We have strived to standardize saliva testing by per-
forming tests at the same time of the day, and instructed
and supervised by the same person (CG). All partici-
pants are fasting 2 h before the testing. This period is
deemed useful to exclude any stimulants (e.g., lunch and
drinking liquid) before testing but might, especially for par-
ticipants with hyposalivation (e.g., participants with un-
stimulated whole saliva flow rate ≤0.10 ml/min), induce
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almost no secretion. Further, we perform in total four saliva
measurements per visit (two tests for whole saliva (un-
stimulated/stimulated), and two tests for the submandibular
glands (unstimulated/stimulated)) totaling to an effective
period of 26 min of saliva testing. This is possibly too ex-
tensive for some participants meaning that the glands will,
when testing the submandibular glands, not be capable of
further secretion. Testing of the submandibular glands is
performed following the stimulated testing of all glands
(whole saliva). It might be an advantage to test the subman-
dibular glands in a post-stimulated state, but it should be
noted that the glands are stimulated. Testing of the sub-
mandibular glands is performed by placement of cotton
rolls at the salivary gland orifices under the tongue, and
consequently the rolls will also collect saliva from the sub-
lingual glands.
We have adjusted numbers of cell according to gland
size based on experience from preclinical studies, but
whether this is transferable to humans and the dose is
adequate remains unknown.
Following the liposuction 12–14 days prior to treat-
ment, a core-needle biopsy of one of the submandibular
glands (participants are randomized for biopsy of either
the right or left gland) is performed. It cannot be ex-
cluded that this procedure might induce salivation and
influence the effect of the ASCs. It is well-documented
that ASCs secrete bioactive molecules that provide a re-
generative microenvironment for a variety of injured
tissues to limit damage and facilitate a regenerative re-
sponse [35]. In this context, it is unknown whether in-
jection to the submandibular glands regenerates only
damaged tissue from the biopsy or also generates new or
improved tissue.
In connection with the injection of the MSCs into the
salivary glands, there is a minimal risk of AEs, such as
pain, infection, and bleeding. The risk of these AEs is
less than 0.5% using similar procedures. A theoretical
risk of a possible carcinogenic effect in the treatment of
MSC has been discussed due to their production of
growth factors such as epidermal growth factor (EGF).
These considerations are particularly relevant since
MSCs are used in participants previously diagnosed with
cancer. However, in model systems of cancer, the effect
of MSCs on cancer growth is controversial as they have
both been shown to be inhibitory and stimulatory [36,
37]. Vascular endothelial growth factor (VEGF) is a
known facilitator of angiogenesis, and might be a medi-
ator of the potential effect of ASCs [38].
Based on numerous trials including studies with
local injection of MSCs with a total of more than
1000 participants no increase in the incidence of can-
cer is detected [39, 40]. Data on ex vivo expanded
MSCs have not, despite extensive research, indicated
malignant transformation [39], including a study that
demonstrated that the injection of a very high dose of
ASCs (240 × 106 MSC/kg) revealed no signs of cancer,
organ toxicity, or change in body weight in mice after
12 months [41].
It is estimated that the risks of AEs in the experiment
is outweighed by the benefits of participation. If the
treatment has a clinically significant effect and is safe,
patients suffering from radiation-induced xerostomia
could be offered a simple, minimally invasive procedure
with few AEs and risks, which is in contrast to the
current suboptimal treatments.
Trial status
This is an investigator-initiated phase I/II trial funded by
Candy’s Foundation. The ethics committees have given
full approval. The date of first enrollment was 22 May
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